Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 9/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.60 |
| ▸ | SMC2 | O95347 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.60 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.60 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22567666 | 0.89 | MAP2K1 (0.58) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL22354901 | 0.86 | MAP2K1 (0.63) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL19014958 | 0.85 | MAP2K1 (0.61) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL2021981 | 0.84 | MAP2K1 (0.47) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL18752668 | 0.83 | MAP2K1 (0.50) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL3859993 | 0.83 | MAP2K1 (0.58) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL18752853 | 0.83 | MAP2K1 (0.47) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL1488195 | 0.82 | MAP2K1 (0.71) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL30733259 | 0.82 | MAP2K1 (0.71) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 | |
| SCHEMBL30746854 | 0.82 | MAP2K1 (0.71) | MAP2K1EGFRMAP2K2SMC2CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023238000-A1 | PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-12-14 | — | — | WO | disclosed |
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-8003805-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100261717-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-1663210-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261717-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAP2K1 164/4885EGFR 206/4885MAP2K2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.